Mesenchymal Stem Cell-Induced Anti-Neuroinflammation Against Traumatic Brain Injury

Blaise Cozene¹, Nadia Sadanandan², Jeffrey Farooq³, Chase Kingsbury³, You Jeong Park³, Zhen-Jie Wang³, Alexa Moscatello³, Madeline Saft⁴, Justin Cho³, Bella Gonzales-Portillo⁵, and Cesar V Borlongan³

Abstract
Traumatic brain injury (TBI) is a pervasive and damaging form of acquired brain injury (ABI). Acute, subacute, and chronic cell death processes, as a result of TBI, contribute to the disease progression and exacerbate outcomes. Extended neuroinflammation can worsen secondary degradation of brain function and structure. Mesenchymal stem cell transplantation has surfaced as a viable approach as a TBI therapeutic due to its immunomodulatory and regenerative features. This article examines the role of inflammation and cell death in ABI as well as the effectiveness of bone marrow-derived mesenchymal stem/stromal cell (BM-MSC) transplants as a treatment for TBI. Furthermore, we analyze new studies featuring transplanted BM-MSCs as a neurorestorative and anti-inflammatory therapy for TBI patients. Although clinical trials support BM-MSC transplants as a viable TBI treatment due to their promising regenerative characteristics, further investigation is imperative to uncover innovative brain repair pathways associated with cell-based therapy as stand-alone or as combination treatments.

Keywords
traumatic brain injury, acquired brain injury, bone marrow-derived mesenchymal stem cells, clinical trials, inflammation, preclinical studies

Introduction
Acquired brain injury (ABI) encompasses any injuries that disturb normal neuronal activity and is not classified as hereditary, degenerative, congenital, or caused by birth trauma. ABI consists of stroke, traumatic brain injury (TBI), aneurysm, tumor, myocardial infarction, and many brain infections. ABI also includes alterations in metabolic activity, disruption to neuronal abilities, or changes in brain structure. Specifically, TBI is a prevalent and damaging form of ABI. A 2016 Global Burden of Disease Study found that there were 27.08 million new TBI cases worldwide with a prevalence of 2,349,017 cases in the United States. Over 5 million Americans currently live with TBI-related disabilities. In Europe, 2012 data revealed that TBI is responsible for approximately 2.1 million yearly hospital discharges as well as 37% of all deaths related to the injury. Common characteristics of TBI consist of bleeding, bruising, and other forms of physical damage to the brain that may result in extended impairment or death. Cognitive features of TBI can include memory, concentration, attention, and thinking deficits, as well as behavioral changes such as mood swings or variations in sleep patterns. The severity of TBI may be estimated by using the Glasgow Coma Scale (GCS), taking into account the duration of impaired/loss of consciousness, and investigating the mechanism of injury. TBI is also associated with an increased frequency of developing neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD), consequently increasing

¹ Tulane University, New Orleans, LA, USA
² Georgetown University, Washington, DC, USA
³ Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, Florida, USA
⁴ University of Michigan, Ann Arbor, MI, USA
⁵ Northwestern University, Evanston, IL, USA

Submitted: February 26, 2021. Revised: June 28, 2021. Accepted: July 12, 2021.

Corresponding Author:
Cesar V Borlongan, Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, Florida 33612, USA.
Email: cborlong@usf.edu
healthcare costs and chronic disability\textsuperscript{6,7}. Although TBI is classified as acute cell death, subacute and chronic cell death are also associated with TBI given the presence of severe inflammatory responses. After TBI, the acute inflammatory response begins immediately, but unresolved damage can lead to subacute or chronic cell death during TBI progression\textsuperscript{1}. Both the central nervous system (CNS) and the peripheral nervous system (PNS) contribute to TBI pathology, and cell-based regenerative medicines serve as potential therapeutic treatments for TBI. Modifications and the use of modern technologies have explored the applicability of bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) for the treatment of TBI\textsuperscript{1}.

**Acute Cell Death Classification of TBI**

Considering the chronological sequence of the cell death cascade following a TBI, the initial insult resulting in primary cell death is recognized as the acute stage, while secondary cell death occurs progressively over the long term during the subacute and chronic stages\textsuperscript{1}. The acute stage of TBI is characterized by sudden and severe cell death, also known as necrosis. Acute cell death can be categorized as either focal or diffuse. Focal refers to acute cell death that occurs within a localized area of the brain, whereas diffuse denotes cell death arising throughout various regions of the brain, including areas that are isolated from the initial injured region of the brain. Additionally, subacute and chronic cell death can spread to regions outside of the brain after the onset of TBI\textsuperscript{1}. Specifically, remote secondary cell death has been observed to occur within the spleen, an organ that plays a key role in the inflammatory response\textsuperscript{1}. This highlights the influence of peripheral factors on the processes underlying subacute and chronic cell death\textsuperscript{3,8,9}. It is important to consider the severity of subacute and chronic cell death with increasing age. A younger brain exhibits more plasticity and may more effectively utilize endogenous repair mechanisms than an adult brain. Although TBI is classified as an acute brain injury, subacute and chronic cell death continues to develop over a drastic time period, and inflammation plays a major role in worsening these degenerative pathways\textsuperscript{9–12}. Given this information, targeting inflammation could point cell-based therapies in the right direction to reduce TBI-associated subacute and chronic cell death.

**Inflammation, Subacute and Chronic Cell Death**

The immune system’s capacity to propagate severe, inappropriate inflammatory responses in peripheral tissues is well established; however, recent evidence now details a similarly compelling role in CNS dysfunction\textsuperscript{13–16}. The CNS is immune privileged to a large extent, and it relies on specialized resident glial cells known as microglia to carry out immunoprotective functions. Typically, peripheral immune cells cannot penetrate the blood–brain barrier (BBB) to enter the cerebrospinal fluid (CSF); however, the acute inflammatory response following a TBI breaches the BBB, allowing for the infiltration of peripheral immune cells into the CSF\textsuperscript{16}. In addition, the acute cell death induced by TBI stimulates proinflammatory microglial cells to mirror the activity of peripheral macrophages by migrating to the site of injury and exacerbating inflammation\textsuperscript{15,16}. Furthermore, inflammatory cytokines released by microglial cells collaterally act on the BBB to increase its permeability enough to allow circulating leukocytes to migrate from the peripheral circulation into the CNS\textsuperscript{17,18}. These leukocytes exhibit a remarkable aptitude toward modulating the glial cells by promoting continuous inflammation that impairs neuronal recovery and exacerbates Wallerian degeneration of axons\textsuperscript{9,19}. Therefore, targeting the immune pathway to ablate the inflammatory response postinsult may be a potent approach to reduce subacute and chronic cell death.

**Acute Inflammation**

The acute inflammatory response begins immediately after TBI. Following initial insult, focal ischemia signals microglia to promote expression of the surface protein cluster of differentiation 14 (CD14)\textsuperscript{19}. CD14 is a pattern recognition receptor that is typically found on circulating monocytes, but following TBI, significantly elevated numbers of CD14+ cells—both activated microglia and peripheral monocytes invading the injury site—have been observed in the perivascular spaces and brain parenchyma, indicating CD14’s role in the neuroimmune response to CNS injury and suggesting that microglia fulfill the role of acute inflammatory mediators within the CNS\textsuperscript{19,20}. CD14 enhances microglia sensitivity to lipopolysaccharides (LPS), which allows microglia to recruit proinflammatory cytokines even more effectively than peripheral macrophages\textsuperscript{21}. Although CD14 also exhibits a neuroprotective role against injury by suppressing LPS-induced nitric oxide generation, alleviating glial neurotoxicity, and inhibiting microglial and astrocyte cell death, the increased expression of this receptor is indicative of TBI-induced acute inflammation, as CD14 generates a heightened inflammatory state in the CNS via microglia recruitment\textsuperscript{21,22}. In addition to expressing this innate immune system receptor, M1-activated microglia secrete the proinflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin 1 beta (IL-1β) into the CSF and systemic circulation while neurons simultaneously stimulate interleukin 6 (IL-6) expression\textsuperscript{17}. Importantly, although M1 microglia are proinflammatory, the M2 variant secretes neuroprotective cytokines including transforming growth factor-beta (TGF-β) and interleukin 10 (IL-10)\textsuperscript{6,23}. Therapeutic strategies that promote differentiation toward M2 may be valuable; however, the dynamic milieu of cytokines, growth factors, and cell signals makes it difficult to maintain discrete phenotypes in vivo\textsuperscript{24}. Indeed, the postinjury microenvironment is replete with a diverse range of proinflammatory and neuroprotective factors.
As the acute inflammatory response begins to wane, the pathological cascade progresses toward the subacute phase. During this time, inflammation progresses through the action of proinflammatory cytokines and the secretion of cellular adhesion molecules (CAMs) and matrix metalloproteinases (MMPs) by damaged neurons, microglia, and immune cells. Circulating leukocytes bind to CAMs to isolate themselves to the site of injury and then extravasate from the vasculature into the tissues. MMPs facilitate this process of leukocyte escape by permeabilizing the BBB, thereby enhancing the entry of inflammatory cells into the cerebral space. This combination of increased permeability, augmented leukocyte localization, and profound inflammation ultimately fosters edema, swelling, and neuronal damage. The continued action of activated microglia, CAM and MMP secretion, and numerous key cytokines eventually leads to the progression into the chronic phase of inflammation.

Although TBI causes acute cell death from the direct physical damage, the mechanistic response associated with the subacute and chronic cell death after the initial impact has been a subject of interest for understanding the pathology and treatments of TBI-induced secondary cell death. Briefly, an insult is quickly followed by a largely insufficient transient neuroprotective reaction mediated by a small subset of microglia that differentiate into the neurotrophic M2 phenotype. These microglia promote neurogenesis and cellular regeneration in key brain regions such as the dentate gyrus (DG) of the hippocampus. However, the protection afforded by this short-lived response is countered by the postinjury chronic inflammatory state. At the site of injury, most microglia differentiate into the M1 subtype acutely, and this proinflammatory subtype may persist for up to 20 years postinjury. Microglia localize directly to the site of injury and to the surrounding tissues as well.

**Microglial Polarization**

As discussed previously, microglia exist as two different phenotypes: M1 (proinflammatory) and M2 (immunosuppressive/neuroprotective). The polarization of microglia is dependent on a variety of stimuli. M1 microglia are associated with the secretion of proinflammatory cytokines (i.e., TNF-z and IL-1b) and the generation of oxidative factors (i.e., nitric oxide and reactive oxygen species). Moreover, M1 microglia serve as the initial protective mechanism against injury but simultaneously generate a heightened inflammatory state. On the other hand, M2 microglia initiate anti-inflammation, damaged tissue rehabilitation, and the restoration of extracellular matrix (ECM). Imbalance of M1/M2 polarization is characteristic of neurodegenerative diseases, such as AD and PD. In TBI, M1 phenotype microglia become prevalent early to sequester cellular and molecular detritus. This early M1 microglial activation is vital for the repair of disrupted brain homeostasis. This activation also creates a toxic environment due to the secretion of inflammatory cytokines and oxidative agents, and if microglia remain activated for too long, inflammation and tissue injury can be exacerbated, leading to neurodegeneration. The imbalance of microglial polarization has risen as a potential therapeutic target in TBI.

**Subacute and Chronic Inflammation**

Unresolved acute inflammation progresses to the subacute and chronic phases which are characterized by severe TBI progression. Severe TBI can result in a coma or a minimally conscious state, followed by a post-traumatic confusion and post-traumatic amnesia. The dynamic relationship between peripheral lymphocytes and CNS microglia determines patient outcomes, with death resulting from an inappropriate balance of these systems. This is observed in patients as some present with cognitive decline for days to years following TBI. Furthermore, microglia have been shown to remain active for up to 1 year in animal models. The communication between the central and peripheral cells occurs through the weakened BBB, which allows the systemic leukocytes and proteins to enter the CNS. The subsequent injury from the chronic pathological presence of these compounds in the cerebral tissues exacerbates intracranial pressure and is tightly correlated with cognitive decline and neurodegeneration. The subacute and chronic cell death from TBI is reminiscent of that seen in ischemic stroke, which triggers an anti-neuron autoimmune response that may either augment or diminish the neuroinflammation.

The peripheral leukocytes’ migration into the cerebral tissue through the disrupted BBB to promote inflammation and activate microglia is key to the pathology of TBI. Once in the brain parenchyma, the neuroinflammation induced by these cells creates a deleterious environment unfavorable to cellular survival. This likely underlies the poor rates of stem cell graft transplant survival in TBI patients and the heightened hippocampal degeneration in the ipsilateral subventricular zone (SVZ) and subgranular zone (SGZ). It may also explain the rapidly emerging link between TBI and the amyloid-beta (Aβ) plaques and neurofibrillary tangles distinctly observed in the brains of AD patients. Although AD is typically thought of as an age-related disease, the presence of Aβ plaques in the brains of a broad age range of TBI patients, including children, suggests a potential link to physical injury. Aβ aggregation impairs microglial cell’s ability to carry out phagocytosis. Importantly, TBI is associated with a number of other major neurological issues, some of which may require several months to manifest. Postmortem analysis of TBI patient’s brains within 2 months of injury demonstrated the presence of proteins associated with neurodegenerative diseases, such as the PD-specific α-synuclein. Remarkably, the dopaminergic neuronal cell loss in PD potentiates a microglial activation similar to that observed in TBI; it is defined by proinflammatory cytokine release in the cerebral tissues and a reactive
gliosis. In PD, damaged neurons secrete α-synuclein, which aggregates into protofibrils at the presynaptic cleft. These harmful accumulations enter the CSF to produce harmful consequences, as identified in the brains of infants and children. This pathological accumulation of α-synuclein in cell bodies or axons may represent a critical relationship between PD, AD, and TBI. Models of spinal cord injury support the finding that microglia are the primary CNS cells that respond to injury, and they remain activated for several months after insult.

Central and Peripheral Sources of Inflammation

After a neurological insult like TBI, both the CNS and PNS play a substantial role in the inflammatory cascade that causes further damage to the neural tissue. The central inflammatory response is identified by microglia and other resident brain immune cells, such as dendritic cells, CNS border-associated macrophages, natural killer cells, and mast cells. The peripheral inflammatory response incorporates more of a systemic response, recruiting immune cells from important organs such as the spleen and thymus. In order to uncover the subacute and chronic cell death cascade that exacerbates the initial TBI, it is critical to investigate the central and peripheral organs involved in neuroinflammation and how those organs contribute to the overall pathology of TBI. It is important to recognize the role that the ligand-receptor pair CCL20-CCR6 has in sending chemical stimuli that recruit immune cells such as dendritic cells and effector/memory T and B cells during an inflammatory event such as TBI.

CCL20 acts as a cytokine for CCR6-expressing leukocytes. In an animal model used to replicate neuroinflammation, experimental autoimmune encephalomyelitis (EAE) model, CCL20 acts as a ligand for the CCR6 receptor, contributing to the signaling of immune cells and Th17 or Th1 cluster of differentiation 4 (CD4+ ) cells that further express proinflammatory cytokines that are observed in chronic brain inflammation. As more CCL20 is present in the choroid plexus, CCR6+ T cells are allowed to infiltrate the CNS in the EAE model and therefore increase T cells occupancy in the brain parenchyma. Furthermore, increased expression of proinflammatory cytokines IL-6 and interleukin 17 (IL-17) upregulate CCL20 translation.

In a lateral fluid percussion model of TBI, CCL20 expression is increased in the spleen and thymus 24 h after insult and the cortex and hippocampus 48 h after insult, suggesting a potential mechanism of action that is fundamental to the role of the periphery in neuroinflammation. It was observed that CCL20 was expressed in the spleen and thymus after TBI before presenting in the brain. Furthermore, after splenectomy, there was reduced expression of CCL20 in the periphery, suggesting that the peripheral immune response may serve as a precursor to CCL20 expression in the CNS, resulting in increased neuronal damage. In addition, other studies suggest that the liver may also increase neuroinflammation after TBI. It was found that deficient Kupffer cells originating from the liver reduced ED-1-positive macrophage and neutrophil migrate into an IL-17-injected brain. Kupffer cells are the most prevalent tissue-resident macrophage and are located in the liver sinusoids. These cells aid in the removal of pathogens and maintaining tissue homeostasis. The peripheral immune response, notably the spleen, works together with the central inflammatory response induced by microglia and inflammatory cytokines. All in all, after TBI, the peripheral and central inflammatory mechanisms contribute to a chronic state of neuroinflammation that results in further damage to neurons and delayed brain repair.

Cell-Based Therapy for TBI

Given that TBI pathology manifests both centrally and peripherally, it may be efficacious to administer cell-based regenerative medicines both intracerebrally and systemically, either by intravenous or intra-arterial injection. In the aged brain, combination therapies of cell transplants and other treatments, such as hypothermia and electrical stimulation, may be needed in order to promote brain repair. Whereas, in younger populations, cell-based therapy may be all that is needed to facilitate neuronal regeneration. In addition, cell transplants may dampen both short-term and long-term inflammation. Immediate administration of cells following TBI seeks to offer neuroprotection by preventing inflammation, apoptosis, mitochondrial dysfunction, and oxidative stress. Meanwhile, long-term administration of cells serves to promote synaptogenesis, neurogenesis, angiogenesis, vasculogenesis, and overall brain repair. It is apparent that increased inflammation is a common factor across most populations and injury sites, and a cell therapy that targets this inflammation can ameliorate and even decelerate the disease progression of TBI by reducing subacute and chronic cell death.

A potential approach to cell-based TBI therapy consists of stimulation of endogenous stem cells. Stimulation of endogenous stem cells shows great therapeutic promise as the mature adult brain has been shown to possess regenerative capabilities in the SVZ and the DG of the hippocampus. Adult stem cells possess the capacity to proliferate and differentiate to renew injured and senescent cells. Moreover, TBI has been shown to induce endogenous repair mechanisms resulting in stem cell proliferation around the SVZ and DG in murine models. Targeting endogenous stem cell populations may provide an effective therapeutic option to treat TBI.

Another promising avenue of cell-based therapy is the transplantation of exogenous stem cells. A wide variety of transplanted exogenous stem cells have been investigated to overcome the limited regenerative capabilities of endogenous brain repair within TBI. Exogenous stem cell transplantation has also demonstrated regenerative capabilities in other neurodegenerative disorders such as stroke. Their
capacity to differentiate and home to the site of injury could provide favorable effects on the injured brain by replacing dysfunctional and senescent neurons. Aside from renewing injured cells, exogenous stem cells may enhance functional improvements via the secretion of many anti-inflammatory molecules, chemokines, cytokines, and growth factors. These molecules can significantly dampen the harsh environment of the inflammation-ridden brain and promote endogenous repair mechanisms.

**Targeting Inflammation with Cell-based Therapy in TBI**

Targeting inflammatory mechanisms in TBI may provide insight on subacute and chronic cell death progression as well as potent treatments. Uncontrolled inflammatory activity in TBI, originating from peripheral and central organs, has been correlated with functional recovery deficits and post-TBI cell deaths. Peripheral organs, specifically the spleen, may serve as potential target tissues for analyzing subacute and chronic cell death mechanisms due to their significant contribution to systemic inflammatory activity. To further understand the pathologies of neuroinflammation and develop anti-inflammatory strategies for TBI, recognizing the importance of central and peripheral systems in TBI progression and tissue damage exacerbation is vital.

**Bone Marrow-Derived Mesenchymal Stem Cells for TBI**

Although the success of stem cell transplantation for TBI-induced neuroinflammation is dependent on translational factors from lab to clinic, the type of stem cell being administered may influence transplantation efficacy the most. Some translational factors include determining the optimal route, dosage, and timing of stem cell treatment. In addition, the safety index of the stem cells must be fully analyzed, as some can be tumorigenic. Ideally, the stem cells should exhibit robust stemness/pluripotency, which is the ability to differentiate into any of the three germ layers. Numerous types of stem cells have been examined to determine their efficacy as cell donors in TBI cell transplantation. For example, embryonic and fetal stem cells possess desired pluripotent characteristics. However, the method of harvest and potential adverse effects, such as the development of tumors, raise ethical and safety concerns in regard to their clinical use, shifting the target to other stem cells, namely adult tissue-derived cells. BM-MSCs exhibit therapeutic effects on the brain similar to that of embryonic and fetal stem cells without notable ethical or safety considerations in addition to its availability and well-supported history, making it a favorable tool for stem cell treatments.

Multiple neurological disease models have highlighted the restorative effects of BM-MSCs in functional recovery. Animal models demonstrated structural brain repairment and improvement in motor and cognitive functions after BM-MSC administration. Specifically, reduced proinflammatory cytokine expression levels, including IL-6, interleukin 1 alpha (IL-1α), and interferon-gamma (IFN-γ), were observed after BM-MSC transplantation via intraventricular infusion. Growth factors released by BM-MSCs may be responsible for the observed therapeutic activity, including neurotrophic exosomes, neurogenesis, angiogenesis, and direct cell replacement. However, specific mechanisms and pathologies have not been discovered. Some studies offered models, such as reductionist cell implantation, to explain the mysterious therapeutic mechanisms of cell implantation. Unfortunately, proposed models were determined to be overly simplistic. Little evidence supporting the mechanism of MSC and study designs...
presenting limitations hindered patient recruitment in clinical trials and inferior brain examinations. Grafted cells were proposed to inherit growth factors that harmoniously reduce inflammation, oxidative stress, and apoptosis in addition to other bystander mechanisms to restore the brain. Bystander mechanisms refer to the ability in which grafted cells bring about both functional and structural restorative benefits and their role in immunomodulation, neurogenesis, brain plasticity, and secretion of neuroprotective factors.

Given that post-TBI inflammation is responsible for subacute and chronic cell death, which further induces cognitive dysfunctions, BM-MSCs are potent treatment options for TBI due to their anti-inflammatory and immunosuppressive abilities. BM-MSC administration via intravenous infusion was seen to lower microglia and immune cells activity at damaged sites in TBI rats. Furthermore, BM-MSC treatment may downregulate or inhibit proinflammatory cytokines while also inducing anti-inflammatory cytokines possibly by suppressing microglial activation. Restorative effects of BM-MSC treatment in TBI rats were also observed by increased neuroprotective properties, improved functional recovery, and neural regeneration. In addition to its therapeutic properties, BM-MSC may have enhanced efficacy in treating TBI if the stem cells were genetically modified. Homing capabilities of BM-MSCs to TBI lesion sites were further improved when the stem cells expressed higher levels of fibroblast growth factor 21 (FGF21). Other TBI rat models highlighted enhanced autoapagy, mitophagy, and immunomodulation activity in BM-MSC with overexpressed anti-inflammatory cytokine IL-10, significantly enhancing neuroprotection and functional recovery.

Coupling cell treatment and other neurological treatments, such as biomaterial, pharmaceutical interventions, and additional cell transplantations, may also significantly improve the cognitive and motor functions of patients undergoing cell therapy. In stroke models, anti-inflammatory activity was evident after coupling BM-MSC with other interventions, such as peroxisome proliferator-activated receptor gamma agonist pioglitazone and regulatory T cells. Combining BM-MSC with other therapeutic methods may introduce enhanced restoration of cognitive function in stroke and TBI-induced neuroinflammation. However, further investigations must be conducted to verify if similar potent effects result when applied to TBI models.

Clinical Perspective on MSC Therapy for TBI

The efficacy and viability of BM-MSCs in the clinical setting still face significant questions and challenges, despite preclinical evidence supporting the feasibility of BM-MSCs in use as cell-based therapy. Transplanted BM-MSCs have demonstrated promising results in animal models. They provide a wide array of functional mechanisms, ranging from endogenous stem cell mobilization, secretion of trophic factors, and to encourage recovery after CNS insults. Moving to the clinical setting proves difficult due to the painful procedure of collecting bone marrow samples. By analyzing the recent data from clinical trials in human subjects, these discrepancies may be resolved for a better understanding of BM-MSC transplantation and the procedure’s utility as a treatment for TBI in the future.

The interactions between grafted or endogenous cells with immune cells have broad implications for regenerative medicine. Both the adaptive (B and T cells) and innate (macrophages, monocytes, microglia) immune systems regulate autonomous mechanisms for cell and non-cell regenerative responses, with postinjury immune responses triggering either increased or reduced inflammation. The circulating population of immune cells infiltrating the graft can also influence grafted cells to regulate the immune response. Major histocompatibility complex (MHC) II expressing macrophages that are cocultured with adipose-tissue derived MSCs demonstrate upregulated collagen settlement via MHC II signaling. Proliferation and expression of MMPI (incites migration of cells), PLOD2 (maintains intermolecular crosslinks), and PTGS2 (regulates the proinflammatory response) are also shown to be accelerated. This evidence supports the role of MSCs in modifying the innate immune response’s role to promote healing; however, there is also evidence that the adaptive immune system hinders the anti-inflammatory and therapeutic response from grafted cells. One method is T cells and NK cells may target stem cells such as MSCs due to MHC I expression, triggering immune-mediated cytolysis. Despite this, MSCs may evade this immune regulation; a study provided evidence that MSCs can physically hinder T cells from contact with antigen-presenting cells which can explain why both naive and memory T-cell response is inhibited in a dose-dependent fashion when cultured together. The interactions between immune cells and stem cell grafts require further investigation into the exact cellular processes, but current evidence has both positive and negative implications for the potential usage of MSCs in TBI.

In a recent clinical trial, autologous BM-MSC transplantation was supported to be safe and effective in a 2013 trial. Ninety-seven patients were administered BM-MSCs via lumbar puncture, with 38 (39.2%) of the patients demonstrating improved neurological function following transplantation. In addition, 27 out of 73 (37.0%) patients presenting with motor disorders showed improvement in motor function, and 11 of 24 patients in a persistent vegetative state showed post-therapeutic improvements in consciousness. While the results do not show BM-MSC transplantation has efficacy in every patient, the study noted variable outcomes based on factors such as patient age and the post-injury administrative window, with a significant correlation of earlier administration and younger patient age with improvement. Another clinical study using BM-MNCs (mononuclear cells) in TBI indicated both safety in bone marrow harvest and an infusion, which is promising for future trials identifying efficacy. Twenty-five patients received
intravenous BM-MNC infusions in a dose-escalation trial (6, 9, 12 × 10^6 cells/kg body weight), without severe adverse effects. Furthermore, paralleling pre-clinical evidence from animal models, the treatment also correlated with a downregulation of inflammatory cytokines IL-1β and IFN-γ. For patients with TBI, the feasibility and safety of performing bone marrow transplantation are supported by these findings.

**Updated Preclinical and Clinical Studies of the Utilization of MSC Therapy on TBI**

Recent studies have further explored the use of MSCs as a therapy to treat TBI. Researchers have also uncovered mechanisms to enhance and maximize the efficacy of MSCs in vivo. The number of recently completed clinical trials that have utilized MSC transplantation is still lacking; however, there are many ongoing and recruiting studies. Updated preclinical evidence warrants the further investigation of MSCs as a potent therapeutic against TBI, and more clinical trials should be conducted. Modification and coupling of MSCs has also been an area of interest and demonstrated beneficial results in a preclinical setting.

MSCs were modified to upregulate and overexpress FGF21. FGF21 has shown to augment angiogenesis, elicit neuroprotective effects, and induce remyelination. The FGF21-enhanced MSCs were administered via intracerebroventricular injection 24 h after TBI in mice. Three to 4 weeks after treatment, the spatial memory deficits, lessened hippocampal neurogenesis, and abnormal dendritic morphology associated with TBI significantly improved. Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) have shown positive results in improving TBI-induced deficits. hUC-MSCs efficacy is impeded by the severe environment of the injured brain. The MG53 protein was investigated in combination with hUC-MSCs to elucidate whether it could facilitate the improved function of the stem cells and help attenuate the oxidative stress that hinders the maximum therapeutic effectiveness of MSCs. Data indicated that MG53 preserved hUC-MSC proliferation and migration by attenuating hydrogen peroxide associated-oxidative damage. Moreover, coupling MG53 and hUC-MSCs in rats relieved brain edema and improved deficits. Apoptosis was observed at a lower rate, and PI3K/Akt-GSK3β signaling was increased. Further exploration of stem cell coupled agents is encouraged to maximize dosage and route of administration to enhance MSC survival and function. MSC therapy to target TBI is often impeded by host immune responses, specifically cytotoxic cluster of differentiation 8 (CD8^+) T cells, which can interrupt therapeutic efficacy. To combat this, an agarose hydrogel was created to induce apoptosis of cytotoxic CD8^+ T cells via secretion of Fas ligand. This treatment mechanism was investigated in tandem with MSC transplantation. When applied in the area of MSC transplantation, a localized decrease in cytotoxic CD8^+ T cells was observed. Furthermore, data indicated augmented levels of neurotrophic factors which consequently improve TBI-associated deficits. Further investigation is warranted on the efficacy of immunosuppressive hydrogels to facilitate stem cell transplantation for neurodegenerative disorders.

**MSC-Derived Exosomes**

Many preclinical investigations suggest that MSC-derived exosomes provide beneficial therapeutic potential. The efficacy of human adipose mesenchymal stem cell-derived exosomes (hADSC-ex) was investigated in a TBI rat model. Data indicated that hADSC-ex attenuated the inflammation associated with TBI via inhibiting microglia and macrophages during injury. By mitigating inflammation, hADSC-ex permitted reduced neuronal apoptosis and enhanced neurogenesis. Furthermore, tested in a swine TBI model, recipients of exosomes displayed decreased lesion size, swelling, and intracranial pressure. Data revealed decreased concentrations of acidic protein levels and augmented concentrations of zonula occludens 1, claudin-5, and laminin. MSC-derived exosomes have the capacity to relieve swelling and fortify BBB integrity. These findings further contribute to MSC-derived exosomes’ therapeutic potential and confirm that MSCs retain their capabilities as a potent treatment within a larger animal model.

**MSC-Derived Secretome**

Another alternative to MSC transplantation is the administration of MSC-derived secretome. Umbilical cord mesenchymal stem cells were pretreated with TBI brain tissue to stimulate the MSC secretome. The traumatic injury-preconditioned secretome delivered increased efficacy in enhancing maturation, differentiation, and migration in the DG when compared to non-preconditioned secretome treatment. Taken together, these beneficial effects could contribute to improvements in cognitive recovery. Secretome therapy proves a beneficial avenue to treat TBI and may be a safer alternative than stem cell transplantation. Adipose-derived mesenchymal stem cell secretome (ASC-ST) collected under hypoxic conditions was injected into TBI rats. Inflammation and vasogenic edema were attenuated by ASC-ST. Furthermore, ASC-ST increased M2 and decreased M1 microglia phenotypes which resulted in a decrease in neuronal apoptosis and nerve fiber damage. Secretome treatment augmented concentrations of TGF-β and tumor necrosis factor-stimulated gene 6 protein while decreasing IL-6 and TNF-α levels. By regulating TBI-induced secondary inflammation, ASC-ST proves very beneficial in treating TBI and other CNS diseases.

**Clinical Studies**

A 2017 clinical trial provided an interesting correlation between hyperbaric oxygen treatment (HBOT) and
mobilization of stem cells. Twenty-eight subjects who suffered TBI during military deployment were analyzed for relative abundance of stem cells in the peripheral blood post-HBOT. Fluorescence-activated cell sorting analysis indicated that HBOT treatment did promote stem cell mobilization and consequently boosted cognition. These effects of HBOT also served to relieve post-traumatic stress. This mechanism should be further explored to possibly couple with MSC transplantation. Although there has been a lack of recently published clinical trials, there are many ongoing and recruiting studies. An active trial has recruited 300 male and female participants who present with CNS damage, including TBI-induced injury. The goal of this study is to test the therapeutic efficacy of bone (BM-MSCs when delivered intranasally or intravenously). Daily activities will be evaluated over the course of a year, and neurological function will be assessed. This study is ongoing, and results have not yet been published. A phase I ongoing trial is currently utilizing adipose tissue derived-mesenchymal stem cells (AD-MSCs) and treating participants 3 times for 6 weeks post-TBI. They plan to analyze inflammatory cytokines as well as neuropsychology, cognition, and neurological function of patients after treatment. They aim to determine the safety of AD-MSC infusion as well as the influence treatment has on the structural integrity of gray and white matter in the corpus callosum. Many studies are also investigating the therapeutic potential of bone marrow mononuclear cells (BMMNCs) within TBI. The aim of one phase I completed trial was to determine the efficacy, safety, and feasibility of BMMNCs. Results indicated no clinically significant side events were induced by transplantation and showed BMMNC’s were a practical and safe treatment. TNF-α concentrations were decreased in patients, and this was also recently observed in rats upon MSC transplantation in TBI. An active phase II trial also utilizing BMMNC’s and aims to investigate the macrostructural and microstructural properties of gray matter, white matter, and corpus callosum integrity. Results have not yet been published.

**Pharmacological Treatments for TBI**

In contrast to cell-based therapies, the use of pharmacological treatments for TBI also demonstrates their efficacy in the laboratory. Cyclooxygenase (COX) inhibition reduces some of the harmful effects associated with brain injury. Carprofen, an anti-inflammatory drug, improves TBI outcomes by decreasing the lesion size and increasing neurogenesis in rodents. Additionally, Rolipram displays neuroprotective effects, improves synaptic plasticity, and improves cognitive performance in a mouse model of TBI. As these pharmacological treatments have been tested in preclinical TBI models and have been shown to be neuroprotective, they remain to experimental therapeutics and await their translation into clinical trials for TBI patients. Combining cell-based treatments with such drugs may enhance their efficacy and provide viable TBI treatment options.

**Conclusion**

Due to the substantial health and economic strain TBIs pose around the world, along with inadequate treatment options call for an advanced therapeutic approach to mitigate disease progression. Resulting acute cell death by TBI causes brain damage that can be categorized as either diffuse or focal. Secondary neurodegeneration is notably influenced by peripheral sources of immune cells and the age of the patient during both the acute and chronic phases after TBI. Neuroinflammation that occurs following TBI closely resembles subacute and chronic neural cell loss progression. Delineating the relationship between the brain, a central source, and the spleen, a peripheral source, is essential in understanding the mechanisms causing neuroinflammation. One novel regenerative biologic therapy that has emerged is MSC transplantation, which targets the neuroinflammation caused by TBI. Enhancements within the cell therapy tactic are necessary to help transplantation strategies accommodate varying brain inflammatory responses. In regard to focal brain injury, the localized intracerebral delivery of MSCs may be a more suitable strategy to directly target the inflamed area. With diffuse brain damage, systemic delivery of MSCs and targeting the spleen could help hinder both central and peripheral sources of inflammation. Although stand-alone MSC transplantation may be adequate enough to initiate neuroprotection and rejuvenation in younger brains, combination therapies could be essential to meet the gold standards of treatment. In addition, recurrent supplementation of MSC infusions throughout the chronic phase following TBI may be needed after the initial MSC injection that is given during the acute phase. Through accumulating preclinical evidence, BM-MSCs have shown the potential to model a propitious cell therapy option due to their anti-inflammatory and immunomodulatory properties. It is suggested to incorporate blinding and sample size calculations, randomization, heterogenous animal genders, at least two different animal models, comorbid animal strains, and investigation of appropriate dose-response relationships. Adhering to these STEPS guidelines will likely produce a safe and effective design framework for the clinical application of MSCs. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS) provide guidance for preclinical testing including cell delivery approaches, such as cell dosing, timing, and route, as well as devices to assist cell delivery, and considerations for clinically relevant animal and human testing. These guidelines have been implemented to facilitate the successful translation of safe and effective cellular therapies from preclinical studies to clinical trials. Use of MSCs with TBI represents a promising therapy technique for future therapeutic ventures that are aimed at treating TBI.
Currently, TBIs possess limited treatment options, especially TBI pathologies caused by acute, subacute, and chronic cell death. BM-MSCs have the potential to fill this treatment gap due to their initial neuroprotective effects and their long-term neuroregenerative and immunomodulatory effects. Successful translation of MSC transplants from the lab to the patient’s bedside could help diminish the health and economic burden caused by TBI. There are currently only a small number of clinical trials that use BM-MSCs for the treatment of TBI despite their positive preclinical results, relative accessibility, and well-established safety record in their use for other disorders. There is a limited capacity for cross-examination of BM-MSC trials due to the varying research designs and dissimilarities between research outcomes. This review emphasizes the necessity for more clinical trials, especially those who follow the STEPS guidelines. These findings stress the importance of addressing the issue of scaling up MSCs since it remains a rate-limiting step in some treatments. This review also brings attention to the interest surrounding MSC transplant administration. This includes the possibility of administration that is in concert with the adaptive and innate immune system of the patient, as well as the characteristics of the patient, injury specifics, dosage, number of doses, and timing. The use of MSC transplants as a therapeutic for TBI has grown exponentially over the past decade and is likely to continue to grow. Upon the discovery of viable approaches that improve cell proliferation, significant scientific milestones may be reached and MSC transplant therapy could become the standard of care for the treatment of TBI. MSC therapy represents a rich area for future research. The desired outcome of this research is the development of a successful and safe cell therapy that helps to rid the subacute and chronic cell death inflammatory response associated with TBI.

Acknowledgments
The authors thank the entire staff of the Borlongan Neural Transplantation Laboratory for critical discussion of this manuscript.

Author Contributions
All authors contributed to the conception, literature analysis, preparation and writing of original draft, and reviewed and edited the manuscript. CVB performed the supervision, project administration and acquisition of funds. All authors have read and agreed to the published version of the manuscript.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: CVB is funded by National Institutes of Health (NIH) R01NS090962, NIH R01NS102395, and NIH R21NS109575.

ORCID iD
Cesar V Borlongan https://orcid.org/0000-0002-2966-9782

References
1. Bonsack B, Corey S, Shear A, Heyck M, Cozene B, Sadana- dan N, Zhang H, Gonzales-Portillo B, Sheyner M, Borlongan CV. Mesenchymal stem cell therapy alleviates the neuroinflammation associated with acquired brain injury. CNS Neurosci Ther. 2020;26(6):603–615.
2. GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(1):56–87.
3. Acosta SA, Tajiri N, Hoover J, Kaneko Y, Borlongan CV. Intravenous bone marrow stem cell grafts preferentially migrate to spleen and abrogate chronic inflammation in stroke. Stroke. 2015;46(9):2616–2627.
4. Majdan M, Plancikova D, Brazinova A, Rusnak M, Nieboer D, Feigin V, Maas A. Epidemiology of traumatic brain injuries in Europe: a cross-sectional analysis. Lancet Public Health. 2016;1(2):e76–e83.
5. Andriessen TM, Horn J, Franschman G, van der Naalt J, Haitsma J, Jacobs B, Steyerberg EW, Vos PE. Epidemiology, severity classification, and outcome of moderate and severe traumatic brain injury: a prospective multicenter study. J Neurotrauma. 2011;28(10):2019–2031.
6. Ramos-Cejudo J, Wisniewski T, Marmar C, Zetterberg H, Blennow K, de Leon MJ, Fossati S. Traumatic brain injury and Alzheimer’s disease: the cerebrovascular Link. EBioMedicine. 2018;28:21–30.
7. Crane PK, Gibbons LE, Dams-O’Connor K, Trittschu E, Leverenz JB, Keene CD, Sonnen J, Montine TJ, Bennet DA, Leurgans S, Schneider JA, et al. Association of traumatic brain injury with late-life neurodegenerative conditions and neuropathologic Findings. JAMA Neurol. 2016;73(9):1062–1069.
8. Ajmo CT Jr, Vernon DO, Collier L, Hall AA, Garbuza- Davis S, Willing A. The spleen contributes to stroke-induced neurodegeneration. J Neurosci Res. 2008;86(10):2227–2234.
9. Marcet P, Santos N, Borlongan CV. When friend turns foe: central and peripheral neuroinflammation in central nervous system injury. Neuroimmunol Neuroinflamm. 2017;4:82–92.
10. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010;87(5):779–789.
11. Acosta SA, Tajiri N, Shinozuka K, Ishikawa H, Grimmig B, Diamond DM, Sanberg PR, Bickford PC, Kaneko Y, Borlongan CV. Long-term upregulation of inflammation and suppression of cell proliferation in the brain of adult rats exposed to traumatic brain injury using the controlled cortical impact model. PLoS One. 2013;8(1):e53376.
12. Lozano D, Gonzales-Portillo GS, Acosta S, de la Pena I, Tajiri N, Kaneko Y, Borlongan CV. Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and
therapeutic opportunities. Neuropsychiatr Dis Treat. 2015;11:97–106.

13. Dantzer R. Neuroimmune interactions: from the brain to the immune system and vice versa. Physiol Rev. 2018;98(1):477–504.

14. Arnoux I, Audinat E. Fractalkine signaling and microglia functions in the developing brain. Neural Plast. 2015;2015:689404.

15. Giunta B, Obregon D, Velisetty R, Sanberg PR, Borlongan CV, Tan J. The immunology of traumatic brain injury: a prime target for Alzheimer’s disease prevention. J Neuroinflammation. 2012;9:185.

16. Ontiveros DG, Tajiri N, Acosta S, Giunta B, Tan J, Borlongan CV. Microglia activation as a biomarker for traumatic brain injury. Front Neurol. 2013;4:30.

17. Shi Y, Zhang L, Pu H, Mao L, Hu X, Jiang X, Xu X, Stetler RA, Zhang F, Liu X, Leak RK, et al. Rapid endothelial cytoskeletal reorganization enables early blood-brain barrier disruption and long-term ischaemic reperfusion brain injury. Nat Commun. 2016;7:10523.

18. Shi Y, Jiang X, Zhang L, Pu H, Hu X, Zhang W, Cai W, Gao Y, Leak RK, Keep RF, Bennet MVL, et al. Endothelium-targeted overexpression of heat shock protein 27 ameliorates blood-brain barrier disruption after ischemic brain injury. Proc Natl Acad Sci U S A. 2017;114(7):E1243–E1252.

19. Borlongan CV, Glover LE, Sanberg PR, Hess DC. Permeating the blood brain barrier and abrogating the inflammation in stroke: implications for stroke therapy. Curr Pharm Des. 2012;18(25):3670–3676.

20. Beschorner R, Nguyen TD, Gözalan F, Pedal I, Mattern R, Schluesener HJ, Meyermann R, Schwab JM. CD14 expression by activated parenchymal microglia/macrophages and infiltrating monocytes following human traumatic brain injury. Acta Neuropathol. 2002;103(6):541–549.

21. Janova H, Böttcher C, Holtman IR, Regen T, van Rossum D, Götz A, Ernst AS, Fritsche C, Gertig U, Saiepour N, Gronke K, a et al. CD14 is a key organizer of microglial responses to CNS infection and injury. Glia. 2016;64(4):635–649.

22. Yin GN, Jeon H, Lee S, Lee HW, Cho JY, Suk K. Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions. J Neurosci Res. 2009;87(11):2578–2590.

23. Appel SH, Zhao W, Beers DR, Henkel JS. The microglial-motoneuron dialogue in ALS. Acta Myol. 2011;30(1):4–8.

24. Rosi S. A polarizing view on posttraumatic brain injury inflammatory response. Brain Circ. 2016;2(3):126–128.

25. Garcia-Culebras A, Durán-Laforet V, Peña-Martínez C, Ballesteros I, Pradiño JM, Díaz-Guzmán J, Lízasoain I, Moro MA. Myeloid cells as therapeutic targets in neuroinflammation after stroke: Specific roles of neutrophils and neutrophil-platelet interactions. J Cereb Blood Flow Metab. 2018;38(12):2150–2164.

26. Faustino J, Chip S, Derugin N, Jullienne A, Hamer M, Haddad E, Butovsky O, Obenaus A, Vexler ZS. CX3CR1-CCR2-dependent monocyte-microglial signaling modulates neurovascular leakage and acute injury in a mouse model of childhood stroke. J Cereb Blood Flow Metab. 2019;39(10):1919–1935.

27. Fukumoto Y, Tanaka KF, Parajuli B, Shibata K, Yoshioka H, Kanemaru K, Gachet C, Ikenaka K, Koizumi S, Kinouchi H. Neuroprotective effects of microglial P2Y(1) receptors against ischemic neuronal injury. J Cereb Blood Flow Metab. 2019;39(11):2144–2156.

28. Kurisu K, Zheng Z, Kim JY, Shi J, Kanoko A, Liu J, Hsieh CL, Yenari MA. Triggering receptor expressed on myeloid cells-2 expression in the brain is required for maximal phagocytic activity and improved neurological outcomes following experimental stroke. J Cereb Blood Flow Metab. 2019;39(10):1906–1918.

29. Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2016;53(2):1181–1194.

30. Donat CK, Scott G, Gentleman SM, Sastre M. Microglial activation in traumatic brain injury. Front Aging Neurosci. 2017;9:208.

31. Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol. 2008;7(8):728–741.

32. Ortega SB, Noorhais I, Ponsatte K, Kong X, Anderson A, Monson NL, Stowe AM. Stroke induces a rapid adaptive autoimmune response to novel neuronal antigens. Discov Med. 2015;19(106):381–392.

33. Dela Peña I, Sanberg PR, Acosta S, Tajiri N, Lin SZ, Borlongan CV. Stem cells and G-CSF for treating neuroinflammation in traumatic brain injury: aging as a comorbidity factor. J Neurosurg Sci. 2014;58(3):145–149.

34. Jordan BD. Chronic traumatic brain injury associated with boxing. Semin Neurol. 2000;20(2):179–185.

35. Bazarian JJ, Cernak I, Noble-Haeusslein L, Potolicchio S, Temkin N. Long-term neurologic outcomes after traumatic brain injury. J Head Trauma Rehabil. 2009;24(6):439–451.

36. Stefanis L. α-Synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(2):a009399.

37. Su E, Bell MJ, Wisniewski SR, Adelson PD, Janesko-Feldman KL, Salonia R, Clark RSB, Kochanek PM, Kagan VE, Bayir H. α-Synuclein levels are elevated in cerebrospinal fluid following traumatic brain injury in infants and children: the effect of therapeutic hypothermia. Dev Neurosci. 2010;32(5-2):385–395.

38. Hawthorne AL, Popovich PG. Emerging concepts in myeloid cell biology after spinal cord injury. Neurotherapeutics. 2011;8(2):252–261.

39. Das M, Leonardo CC, Rangooni S, Pennypacker KR, Mohapatra S, Mohapatra SS. Lateral fluid percussion injury of the brain induces CCL20 inflammatory chemokine expression in rats. J Neuroinflammation. 2011;8:148.

40. Das M, Mohapatra S, Mohapatra SS. New perspectives on central and peripheral immune responses to acute traumatic brain injury. J Neuroinflammation. 2012;9:236.

41. Druden D, Pavlovic A, Hartmann FJ, Schreiner B, Utz SG, Leung BP, Lelios I, Heppner FL, Kipnis J, Merkler D, Greter M, et al. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity. 2018;48(2):380–395.e6.
56. Martinez-Monedero R, Oshima K, Heller S, Edge ASB. The potential role of endogenous stem cells in regeneration of the inner ear. Hear Res. 2007;227(1-2):48–52.
70. Dabrowska S, Andrzejewska A, Lukomska B, Janowski M. Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles. J Neuroinflammation. 2019;16(1):178.

71. Zanier ER, Pischiutta F, Riganti L, Marchesi F, Turola E, Fumagalli S, Peregó C, Parotto E, Vinci P, Vegliante P, D’Amico G, et al. Bone marrow mesenchymal stromal cells drive protective M2 microglia polarization after brain trauma. Neurotherapeutics. 2014;11(3):679–693.

72. Anbari F, Khalili MA, Bahrami AR, Khoradmehr A, Sadeghian F, Fesahat F, Nabi A. Intravenous transplantation of bone marrow mesenchymal stem cells promotes neural regeneration after traumatic brain injury. Neuro Regen Res. 2014;9(9):919–923.

73. Mahmood A, Lu D, Chopp M. Intravenous administration of marrow stromal cells (MSCs) increases the expression of growth factors in rat brain after traumatic brain injury. J Neurotrauma. 2004;21(1):33–39.

74. Hasen A, Deeb G, Rahal R, Atwi K, Mondello S, Marei HE, Gali Amr, Sleiman E. Mesenchymal stem cells in the treatment of traumatic brain injury. Front Neurosci. 2017;8:28.

75. Maiti P, Peruzzaro S, Kolli N, Andrews M, Al-Gharaibeh A, Rossignol J, Dunbar GL. Transplantation of mesenchymal stem cells overexpressing interleukin-10 induces autophagy response and promotes neuroprotection in a rat model of TBI. J Cell Mol Med. 2019;23(8):5211–5224.

76. Peruzzaro ST, Andrews MMM, Al-Gharaibeh A, Pupiec O, Resk M, Story D, Maiti P, Rossignol J, Dunbar GL. Transplantation of mesenchymal stem cells genetically engineered to overexpress interleukin-10 promotes alternative inflammatory response in rat model of traumatic brain injury. J Neuroinflammation. 2019;16(1):2.

77. Kinouchi T, Kitazato KT, Shimada K, Yagi K, Tada Y, Matsushita N, Kurashiki Y, Satomi J, Sata M, Nagahiro S. Treatment with the PPARgamma agonist pioglitazone in the early post-ischemia phase inhibits pro-inflammatory responses and promotes neurogenesis via the activation of innate- and bone marrow-derived stem cells in rats. Transl Stroke Res. 2018;9(3):306–316.

78. Neal EG, Acosta SA, Kaneko Y, Ji X, Borlongan CV. Regulatory T-cells within bone marrow-derived stem cells actively confer immunomodulatory and neuroprotective effects against stroke. J Cereb Blood Flow Metab. 2019;39(9):1750–1758.

79. Borlongan CV, Stahl CE, Cameron DF, Saporta S, Freeman TB, Cahill DW, Sanberg PR. CNS immunological modulation of neural graft rejection and survival. Neuro Res. 1996;18(4):297–304.

80. Saporta S, Cameron DF, Borlongan CV, Sanberg PR. Survival of rat and porcine Sertoli cell transplants in the rat striatum without cyclosporine-A immunosuppression. Exp Neurol. 1997;146(2):299–304.

81. Zigova T, Willing AE, Tedesco EM, Borlongan CV, Saporta S, Snable GL, Sanberg PR. Lithium chloride induces the expression of tyrosine hydroxylase in hNT neurons. Exp Neurol. 1999;157(2):251–258.

82. Borlongan CV, Su TP, Wang Y. Treatment with delta opioid peptide enhances in vitro and in vivo survival of rat dopaminergic neurons. Neuroreport. 2000;11(5):923–936.

83. Nishino H, Borlongan CV. Restoration of function by neural transplantation in the ischemic brain. Prog Brain Res. 2000;127:461–476.

84. Liu X, Ye R, Yan T, Yu SP, Wei L, Xu G, Fan X, Jiang Y, Stetler RA, Liu G, Chen J. Cell based therapies for ischemic stroke: from basic science to bedside. Prog Neurobiol. 2014;115:92–115.

85. Kaehler S, Pantcheva P, Borlongan CV. Drug- and cell-based therapies for targeting neuroinflammation in traumatic brain injury. Neuro Regen Res. 2016;11(10):1575–1576.

86. Mashkouri S, Crowley MG, Liska MG, Corey S, Borlongan CV. Utilizing pharmacotherapy and mesenchymal stem cell therapy to reduce inflammation following traumatic brain injury. Neuro Regen Res. 2016;11(9):1379–1384.

87. Krampaer M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101(9):3722–3729.

88. Kokaia Z, Martino G, Schwartz M, Lindvall O. Cross-talk between neural stem cells and immune cells: the key to better brain repair? Nat Neurosci. 2012;15(8):1078–1087.

89. Grotenhuis N, De Witte SF, van Osch GJ, Bayon Y, Lange JF, Bastiaansen-Jenniskens YM. Biomaterials influence macrophage-mesenchymal stem cell interaction in vitro. Tissue Eng Part A. 2016;22(17-18):1098–1107.

90. Morganti JM, Riparip LK, Rosi S. Call Off the Dog(ma): M1/M2 polarization is concurrent following traumatic brain injury. PLoS One. 2016;11(1):e0148001.

91. Tian C, Wang X, Wang X, Wang L, Wang X, Wu S, Wan Zhixian. Autologous bone marrow mesenchymal stem cell therapy in the subacute stage of traumatic brain injury by lumbar puncture. Exp Clin Transplant. 2013;11(2):176–181.

92. Cox CS Jr., Hetz RA, Liao GP, Aertker BM, Ewing-Cobbs L, Bellamkonda RV. Immuno-suppressive hydrogels enhance allogeneic MSC survival after transplantation in the injured brain. Biomaterials. 2021;266:120419.
96. Chen Y, Li J, Ma B, Li N, Wang S, Sun Z, Xue C, Han Q, Wei J, Zhao RC. MSC-derived exosomes promote recovery from traumatic brain injury via microglia/macrophages in rat. Aging. 2020;12(18):18274–18296.
97. Williams AM, Bhatti UF, Brown JF, Biesterfeld BE, Kathawate RG, Graham NJ, Chtraklin K, Siddiqui AZ, Dekker SE, Andjelkovic A, Higgins GA, et al. Early single-dose treatment with exosomes provides neuroprotection and improves blood-brain barrier integrity in swine model of traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg. 2020;88(2):207–218.
98. Liu X, Wei M, Liang J, Xu H, Wang J, Wang J, Yang X, Lv F, Wang K, Duan J, Tu Y, et al. Injury-preconditioning secretome of umbilical cord mesenchymal stem cells amplified the neurogenesis and cognitive recovery after severe traumatic brain injury in rats. J Neurochem. 2020;153(2):230–251.
99. Xu C, Diao YF, Wang J, Liang J, Xu HH, Zhao ML, Zheng B, Luan Z, Wang JJ, Yang XP, Wei MG, et al. Intravenously infusing the secretome of adipose-derived mesenchymal stem cells ameliorates neuroinflammation and neurological functioning after traumatic brain injury. Stem Cells Dev. 2020;29(4):222–234.
100. Shandley S, Wolf EG, Schubert-Kappan CM, Baugh LM, Bell WJ, Bintz B, Schneider P, Chu Y, Babu RS, Borlongan CV, et al. Extensive neuroprotection by choroid plexus transplantation in excitotoxin lesioned monkeys. Neurobiol Dis. 2006;23(2):471–480.
101. Scelpici G, Silvestro S, Bramanti P, Mazzon E. Traumatic brain injury and stem cells: an overview of clinical trials, the current treatments and future therapeutic approaches. Medicina (Kaunas). 2020;56(3):137.
102. Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Ischemic Stroke (AMETIS) [Internet] https://clinicaltrials.gov/ct2/show/NCT01468064 (accessed, July 22, 2021).
103. A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy Status: Recruiting [Internet]. https://ClinicalTrials.gov/show/NCT04063215 (accessed July 22, 2021).
104. Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells Status: Completed [Internet]. https://ClinicalTrials.gov/show/NCT01575470 (accessed July 22, 2021).
105. Autologous Stem Cell Study for Adult TBI (Phase 2b) Status: Enrolling by invitation [Internet]. https://ClinicalTrials.gov/show/NCT02525432 (accessed July 22, 2021).
106. Thau-Zuchman O, Shohami E, Alexandrovich AG, Trembovler V, Leker RR. The anti-inflammatory drug carprofen improves long-term outcome and induces gliogenesis after traumatic brain injury. J Neurotrauma. 2012;29(2):375–384.
107. Atkins CM, Cepero ML, Kang Y, Liebl DJ, Dietrich WD. Effects of early rolipram treatment on histopathological outcome after controlled cortical impact injury in mice. Neurosci lett. 2013;532:1–6.
108. Titus DJ, Sakurai A, Kang Y, Furunes C, Jergova S, Santos R, Sick TJ, Atkins CM. Phosphodiesterase inhibition rescues chronic cognitive deficits induced by traumatic brain injury. J Neurosci. 2013;33(12):5216–5226.
109. Lucke-Wold BP, Logsdon AF, Nguyen L, Eltanahay A, Turner RC, Bonasso P, Knotts C, Moeck A, Maroon JC, Bailes JE, Rosen CL. “Supplements, nutrition, and alternative therapies for the treatment of traumatic brain injury.” Nutr Neurosci. 2018;21(2):79–91.
110. Yasuhara T, Kawauchi S, Kin K, Morimoto J, Kamera M, Sasaki T, Bonsack B, Kingsbury C, Tajiri N, Borlongan CV, Date I. Cell therapy for central nervous system disorders: Current obstacles to progress. CNS Neurosci Ther. 2020;26(6):595–602.
111. Shojo H, Kaneko Y, Mabuchi T, Kibayashi K, Adachi N, Borlongan CV. Genetic and histologic evidence implicates role of inflammation in traumatic brain injury-induced apoptosis in the rat cerebral cortex following moderate fluid percussion injury. Neuroscience. 2010;171(4):1273–1282.
112. Lippert T, Borlongan CV. Prophylactic treatment of hyperbaric oxygen treatment mitigates inflammatory response via mitochondria transfer. CNS Neurosci Ther. 2019;25(8):815–823.
113. Borlongan CV, Sanberg PR, Freeman TB. Neural transplantation for neurodegenerative disorders. Lancet. 1999;353(Suppl 1):S129–S130.
114. Dang DD, Saiyin H, Yu Q, Liang WM. Effects of sevoflurane preconditioning on microglia/macrophage dynamics and phagocytosis profile against cerebral ischemia in rats. CNS Neurosci Ther. 2018;24(6):564–571.
115. Emerich DF, Thanos CG, Goddard M, Skinner SJ, Geany MS, Bell WJ, Bintz B, Schneider P, Chu Y, Babu RS, Borlongan CV, et al. Extensive neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeys. Neurobiol Dis. 2006;23(2):471–480.
116. Greig NH, Lecca D, Hseuh S, Nogueras-Ortiz C, Kapogiannis D, Tweedie D, Glotfelty EJ, Becker RE, Chiang YH, Hoffer BJ. (-)-Phenserine tartrate (PhenT) as a treatment for traumatic brain injury. J Neurosci. 2013;33(12):5216–5226.
117. Xia CF, Yin H, Borlongan CV, Chao J, Chao L. Adrenomedullin gene delivery protects against cerebral ischemic injury by promoting astrocyte migration and survival. Hum Gene Ther. 2004;15(12):1243–1254.
118. Li D, Ji J, Xu Y, Ni H, Rui Q, Liu H, Jiang F, Gao R, Chen G. Inhibition of Lats1/p-YAP1 pathway mitigates neuronal apoptosis and neurological deficits in a rat model of traumatic brain injury. CNS Neurosci Ther. 2018;24:906–916.
119. Stem Cell Therapies as an Emerging Paradigm in Stroke Participants. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke. 2009;40(2):510–515.